Get notified when SCTX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (new) — Management disclosed substantial doubt about the company's ability to continue as a going concern, stating that as of March 31, 2026, existing cash of $49.7M is insufficient to fund operations for twelve months without this offering.
  • Material Weakness (new) — The filing discloses potential material weaknesses in internal controls over financial reporting, which could result in an adverse market reaction due to loss of confidence in the reliability of financial statements.
SCTX Scribe Therapeutics, Inc. S-1

Scribe Therapeutics files for IPO to fund CRISPR cardiovascular therapies; terms not yet set

Filed July 2, 2026 · ~3 min read

Offering filing cluster

Same offering
  1. S-1 Jul 2, 2026 This filing EDGAR →
  2. S-1/A Jul 10, 2026 No report yet EDGAR →
  3. S-1/A Jul 20, 2026 No report yet EDGAR →

Key Changes

  • high

    Scribe Therapeutics, a clinical-stage CRISPR gene-editing biotech, filed an S-1 for an IPO with offering size and price range not yet disclosed. The company will use net proceeds to advance lead candidate STX-1150 (LDL cholesterol lowering) and pipeline programs STX-1200 and STX-1400.

    The Offering verify on EDGAR →
  • high

    The company reported a GAAP net loss of $17.4M for Q1 2026 (vs. $3.4M in Q1 2025), driven by an 87% decline in collaboration revenue from $17.1M to $2.2M due to a non-recurring Lilly milestone in the prior year. Full-year 2025 net loss was $21.8M; accumulated deficit stands at $175.1M.

    Management's Discussion and Analysis verify on EDGAR →
  • high

    As of March 31, 2026, Scribe held $49.7M in cash and investments against $40.5M in debt. Management disclosed substantial doubt about the company's ability to continue as a going concern, stating existing cash is insufficient to fund operations for twelve months without this offering.

    Risk Factors verify on EDGAR →

5 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ISNR 10-Q) is open in full — no account needed.

Partner

Trade SCTX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Source-verified from EDGAR · Narrative written by AI · Jul 20, 2026 · How we verify